- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05935748
Étude Ph2 NKT2152 avec palbociclib et sasanlimab chez des sujets atteints d'un carcinome rénal à cellules claires avancé (ccRcc)
Un essai de phase 2 pour évaluer l'innocuité et l'efficacité du NKT2152 en association avec le palbociclib (doublet) et avec le palbociclib et le sasanlimab (triplet) chez des sujets atteints d'un carcinome rénal à cellules claires avancé ou métastatique
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.
Aperçu de l'étude
Statut
Les conditions
- Tumeurs
- Cancer du rein
- Tumeurs rénales
- Carcinome à cellules rénales
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies rénales
- Maladies urologiques
- Adénocarcinome
- Carcinome
- Tumeurs, glandulaires et épithéliales
- Carcinome rénal à cellules claires
- Carcinome rénal métastatique
- Carcinome à cellules rénales récurrent
- Cancer du rein
- Carcinome à cellules rénales avancé
- Tumeurs rénales
- ccRCC
- Carcinome rénal réfractaire
- Tumeur par histologie
Intervention / Traitement
Description détaillée
This is a Phase 2 open-label, multicenter, global study of NKT2152. This study is designed as two phases: a Lead-in phase and an Expansion phase. Patients must be 18 years or older, with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Eligible patients must have progressed or relapsed after at least 1 prior anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) systemic therapy and 1 immune checkpoint inhibitor (ICI) for advanced or metastatic ccRCC alone or in combination.
The Lead-in phase is designed as a dose escalation phase to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.
The subsequent Expansion phase will evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
La Jolla, California, États-Unis, 92093
- University of California San Diego
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University - Feinberg School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan-Rogel Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130
- Nebraska Cancer Specialists
-
-
New York
-
New York, New York, États-Unis, 10065-6094
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, États-Unis, 75390-9324
- UT Southwestern Medical Center
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- University of Virginia Health System
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI.
- Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
- KPS score of at least 70%
- Able to swallow oral medications.
Exclusion Criteria:
- Active CNS metastases and/or carcinomatous meningitis
- Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease
- Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug.
- Has known HIV
- History of hepatitis B or known active hepatitis C infection
- Has received prior treatment with NKT2152, other HIF2α inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab
- Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment
- Corrected QT interval calculated by Fridericia formula (QTcF) > 480 ms within 28 days prior to first dose
- Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past
- Has a history of interstitial lung disease
- Has any active or recent history of a known or suspected autoimmune disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Lead-in Doublet combination
Lead-in Doublet assesses safety of oral dosing NKT2152 at increasing dosage levels in combination with palbociclib to determine a recommended dose for expansion (RDE). |
Oral HIF2a inhibitor a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Autres noms:
|
|
Expérimental: Lead-in Triplet combination
Lead-in Triplet assesses the safety of two doses of NKT2152 identified in the Doublet arm (RDE and RDE-1) by orally dosing ccRCC patients with NKT2152 in combination with palbociclib and sasanlimab |
Oral HIF2a inhibitor a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Autres noms:
an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration |
|
Expérimental: Expansion Doublet combination
Subjects randomized to Arm 1 will receive the Doublet combination (NKT2152 in combination with palbociclib) to provide an assessment of anti-tumor activity and to determine the RP2D. |
Oral HIF2a inhibitor a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Autres noms:
|
|
Expérimental: Expansion Triplet combination
Subjects randomized to Arm 2 will receive the Triplet therapy (NKT2152 in combination with palbociclib and sasanlimab) to provide an assessment of anti-tumor activity and to determine the RP2D. |
Oral HIF2a inhibitor a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Autres noms:
an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicity (DLT) Events During the DLT Monitoring Period (First 28 Days of Dosing) in the Lead-in Phase
Délai: 28 days
|
Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period. DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0. |
28 days
|
|
Objective Response Rate (ORR) Determined by the Investigator
Délai: 1 years
|
ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
1 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free Survival (PFS)
Délai: 2 years
|
PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death. |
2 years
|
|
Duration of Response (DOR)
Délai: 1 years
|
Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first. |
1 years
|
|
Time to Response (TTR)
Délai: 1 years
|
TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed. |
1 years
|
|
Overall Survival (OS)
Délai: 2 years
|
OS defined as the time from the date the participant started study drug to death for any reason. |
2 years
|
|
Clinical Benefit Rate (CBR)
Délai: 1 years
|
CBR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
1 years
|
|
Number of Participants With Adverse Events
Délai: 2 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. |
2 years
|
|
Maximum Observed Plasma Concentration (Cmax) of NKT2152
Délai: C1D1 (1-24hr post-dose)
|
Maximum observed plasma concentration (Cmax) of NKT2152 on C1D1 (1, 2, 4, 6, and 24 hours post-dose) |
C1D1 (1-24hr post-dose)
|
|
Time to Maximum Observed Plasma Concentration of NKT2152 (Tmax)
Délai: C1D1 (1-24hr post-dose)
|
Time to maximum observed plasma concentration of NKT2152 (Tmax) on C1D1 |
C1D1 (1-24hr post-dose)
|
|
Observed Trough Concentration of NKT2152 (Ctrough)
Délai: C1D1 (1-24hr post-dose)
|
Observed trough concentration of NKT2152 (Ctrough) for single dose (1, 2, 4, 6, and 24 hours post-dose) |
C1D1 (1-24hr post-dose)
|
|
Area Under the Plasma Concentration Time Curve (AUC0-t) of NKT2152
Délai: C1D1 and C1D8 (0-24hr post-dose)
|
Area under the plasma concentration time curve (AUC0-t) of NKT2152 at C1D1 (1, 2, 4, 6, and 24 hours post-dose) and C1D8 (pre-dose, 1, 2, 4, 6, and 24 hours post-dose) |
C1D1 and C1D8 (0-24hr post-dose)
|
|
Accumulation Ratio of NKT2152 (RAC)
Délai: C1D1 and C1D8 (0-24hr post-dose)
|
Accumulation Ratio of NKT2152 (RAC) calculated as C1D8 AUC0-t divided by C1D1 AUC0-t |
C1D1 and C1D8 (0-24hr post-dose)
|
|
Maximum Observed Plasma Concentration (Cmax) of Palbociclib
Délai: C1D1 (1-24hr post-dose)
|
Maximum observed plasma concentration (Cmax) of palbociclib on C1D1 (1, 2, 4, 6, and 24 hours post-dose) |
C1D1 (1-24hr post-dose)
|
|
Time to Maximum Observed Plasma Concentration of Palbociclib (Tmax)
Délai: C1D1 (1-24 hr post-dose)
|
Time to maximum observed plasma concentration of palbociclib (Tmax) on C1D1 (1, 2, 4, 6, and 24 hours post-dose) |
C1D1 (1-24 hr post-dose)
|
|
Observed Trough Concentration of Palbociclib (Ctrough)
Délai: C1D1 (1-24 hr post-dose)
|
Observed trough concentration of palbociclib (Ctrough) on C1D1 (1, 2, 4, 6, and 24 hours post-dose) |
C1D1 (1-24 hr post-dose)
|
|
Area Under the Plasma Concentration Time Curve (AUC0-t) of Palbociclib
Délai: C1D1 and C1D15 (0-24hr post-dose)
|
Area under the plasma concentration time curve (AUC0-t) of palbociclib at C1D1 (1, 2, 4, 6, and 24 hours post-dose) and C1D15 (pre-dose, 1, 2, 4, 6, and 24 hours post-dose) |
C1D1 and C1D15 (0-24hr post-dose)
|
|
Accumulation Ratio of Palbociclib (RAC)
Délai: C1D1 and C1D15 (0-24hr post-dose)
|
Accumulation Ratio of palbociclib (RAC) calculated as C1D15 AUC0-t divided by C1D1 AUC0-t |
C1D1 and C1D15 (0-24hr post-dose)
|
|
Observed Trough Concentration of Sasanlimab (Ctrough)
Délai: 1 years
|
Observed trough concentration of sasanlimab (Ctrough) |
1 years
|
|
Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Délai: 1 years
|
Maximum observed plasma concentration (Cmax) of sasanlimab |
1 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs par type histologique
- Tumeurs
- Carcinome
- Maladies urologiques
- Carcinome à cellules rénales
- Adénocarcinome
- Tumeurs urologiques
- Tumeurs, glandulaires et épithéliales
- Maladies rénales
- Tumeurs rénales
- Tumeurs urogénitales
- Tumeurs par site
- palbociclib
Autres numéros d'identification d'étude
- NKT2152-202
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD are not planned to be shared at this time
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .